Preclinical Translational Cancer Research Program

临床前转化癌症研究计划

• 批准号: 10177892
• 负责人: MIN LI
• 金额: $ 5.38万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10177892
• 关键词: Applications Grants; Award; Cancer Center; Cancer Center Planning Grant; Cancer Center Support Grant; Cancer Control; Cancer Detection; Cancer Research Project; Centers of Research Excellence; Collaborations; Colorectal Cancer; Development; Diagnosis; Direct Costs; Disease; Enhancement Technology; Environment; Foundations; Funding; Generations; Goals; Image; Imaging technology; Institution; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of pancreas; Medical Research; Mentors; Neoplasm Metastasis; Oklahoma; Peer Review; Pilot Projects; Prevention; Publications; Publishing; Reporting; Research; Research Personnel; Resource Sharing; Science; Scientific Advances and Accomplishments; Services; Site; Technology; Translating; Translational Research; Translations; United States National Institutes of Health; cancer prevention; cancer therapy; cell stroma; improved; inter-institutional; member; nanomaterials; neoplastic cell; new technology; novel; novel strategies; pre-clinical; predicting response; programs; response; tool; translational cancer research; translational scientist; tumor growth; tumor progression; tumorigenesis

PRECLINICAL TRANSLATIONAL CANCER RESEARCH PROGRAM – ABSTRACT The goal of the Preclinical Translational Cancer Research (PTCR) program at the Stephenson Cancer Center (SCC) is to promote and accelerate scientific discovery and development of ideas in order to improve the prevention, diagnosis and treatment of cancer. PTCR members represent broad transdisciplinary expertise, from elucidating basic mechanisms of tumorigenesis to conducting preclinical translational research, creating a robust environment for the generation and translation of ideas. The program Specific Aims are: 1) to discover cellular mechanisms that regulate tumor growth, progression and response to therapy; 2) to determine the functional mechanisms underlying tumor cell-stroma interactions leading to tumor progression and metastasis; and 3) to develop novel tools and applications for nanomaterial and imaging technologies that enhance cancer detection, response prediction and treatment. Highlights of the PTCR program include: 1) highly interactive teams of basic discovery and translational scientists organized to advance specific aims; 2) a strong team of basic discovery researchers with a track record of high-impact publications and peer-reviewed funding at the Oklahoma Medical Research Foundation (OMRF), the SCC's proposed consortium partner; 3) integrated and collaborative research with nanomaterials and imaging investigators at OU Norman; 4) access to SCC shared resources, which provide state-of-the-art technologies and services to support program science; 5) disease-site focused transdisciplinary research teams in colorectal and pancreatic cancers, supported by SCC developmental funds, that are developing multi- PI grant applications; and 6) a strong focus on mentoring highlighted by an NIH-funded Center of Biomedical Research Excellence P20 grant. The PTCR program has 46 members that represent 19 departments and two institutions (OU and OMRF), illustrating its transdisciplinary expertise. It is also highly collaborative: of the 15 PTCR pilot projects funded over the past two years, 10 have intra- and seven have inter-programmatic collaborations. As of December 31, 2016, program members were awarded $6,525,844 in annual NCI and other peer-reviewed cancer-related support (direct cost). NCI funding ($2,915,115) accounts for 44.7% of the peer-reviewed funding, highlighting the program's cancer focus. Total annual PTCR program funding is $9,101,794 (direct cost). For the five-year reporting period (2012-2016), PTCR program members published 446 peer-reviewed articles, of which 16.4% included intra-programmatic, 6.1% included inter-programmatic, and 69.7% included inter-institutional collaborators. For 2016, inter-programmatic publications increased to 14.9%, highlighting the growing number of collaborations underway with the Gynecologic Cancers (GC) and Cancer Prevention and Control (CPC) programs.

临床前转移性癌症研究-摘要 斯蒂芬森癌症中心临床前转化癌症研究（PTCR）项目的目标是 (SCC)是促进和加速科学发现和思想的发展，以提高 癌症的预防、诊断和治疗。PTCR成员代表了广泛的跨学科专业知识， 从阐明肿瘤发生的基本机制到进行临床前转化研究， 为思想的产生和翻译提供强大的环境。该计划的具体目标是：1）发现 调节肿瘤生长、进展和治疗反应的细胞机制; 2）确定 肿瘤细胞-基质相互作用导致肿瘤进展和转移的功能机制; 以及3）开发纳米材料和成像技术的新工具和应用，以增强癌症 检测、反应预测和治疗。 PTCR计划的亮点包括：1）高度互动的基础发现和翻译团队 科学家组织起来推进特定的目标; 2）一个强大的基础发现研究人员团队， 俄克拉荷马州医学研究基金会的高影响力出版物和同行评审资助记录 （OMRF），SCC的拟议财团合作伙伴; 3）与纳米材料的综合和合作研究 和影像学研究人员; 4）访问SCC共享资源，提供最先进的 支持项目科学的技术和服务; 5）以疾病部位为重点的跨学科研究 在SCC发展基金的支持下，结肠直肠癌和胰腺癌的团队正在开发多- PI补助金申请;以及6）NIH资助的生物医学中心强调的对指导的强烈关注 卓越研究P20补助金。 PTCR计划有46名成员，代表19个部门和两个机构（OMR和OMRF）， 展示了其跨学科的专业知识。它也是高度合作的：在15个PTCR试点项目中， 在过去两年中，有10个方案进行了方案内协作，7个方案进行了方案间协作。截至12月31日， 2016年，项目成员获得了年度NCI和其他同行评审癌症相关奖励6，525，844美元 直接费用（Direct Cost）。NCI资金（2，915，115美元）占同行评审资金的44.7%，强调 该计划的癌症焦点。PTCR计划的年度总资金为9，101，794美元（直接成本）。五年 报告期内（2012-2016年），PTCR项目成员发表了446篇同行评审文章，其中16.4% 包括方案内，6.1%包括方案间，69.7%包括机构间 合作者2016年，跨计划出版物增加到14.9%，突出了不断增长的数量 与妇科癌症（GC）和癌症预防和控制（CPC）正在进行的合作 程序.